CurrentNeighborhood Health Plan of Rhode IslandPolicy 1975-A

Acamprosate calcium prior authorization for alcohol use disorder

Defines prior authorization criteria and duration of approval for acamprosate calcium for members with alcohol use disorder, including required clinical conditions and programmatic supports.

Policy Summary

PayerNeighborhood Health Plan of Rhode Island

PolicyAcamprosate calcium prior authorization for alcohol use disorder

Policy CodePolicy 1975-A

Change TypeNo material change

Effective Date

Next Review Date

Key ActionObtain prior authorization and document DSM-5 alcohol use disorder, abstinence at treatment initiation, and participation in a comprehensive program including psychosocial support.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

12 monthsDuration of approval

1DSM-5 diagnosis required

requiredPsychosocial support

Coverage Criteria for Acamprosate Calcium

Coverage Criteria

Covered with prior authorization when the following are met:

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Main coverage requirements: The patient has a diagnosis of alcohol use disorder (DSM-5); the drug will be used as part of a comprehensive management program that includes psychosocial support; the patient is, or will be, abstinent from alcohol at treatment initiation; and either the request is for initial therapy or, for continuation/restart, the patient has achieved or maintained a positive clinical response or the drug is being restarted due to relapse after prior improvement.

See continuation-specific documentation requirements for continuation/restart requests.

The available evidence indicates that efficacy has not been demonstrated in patients who have not undergone detoxification and who are not abstinent prior to treatment initiation. In practice, this means that acamprosate is intended for use after a patient has achieved alcohol abstinence (e.g., following detoxification or a period of sustained abstinence) and initiation in actively drinking individuals or those who have not completed detoxification is not supported by demonstrated benefit.

Provider Actions, Authorization & Documentation

Prior Authorization

Prior Authorization Required

Prior authorization is required for coverage of the requested medication. Requests must meet the coverage criteria (DSM-5 diagnosis of alcohol use disorder) and be submitted as an initial therapy request unless continuation criteria are being sought separately.

Prior authorization required for initial requests
Ensure request documents DSM-5 AUD diagnosis

Denial Risk

Coverage prerequisites & Abstinence at initiation

Requests for initial therapy will be denied if the medication is not being prescribed as part of a comprehensive management program that includes psychosocial support or if the patient is not abstinent (or will not be abstinent) from alcohol at treatment initiation. Continuation (renewal) requests are treated separately and must follow the policy's continuation criteria.

Medication must be part of a comprehensive program including psychosocial support
Initial requests: patient must be abstinent from alcohol at treatment initiation
Continuation requests: submit under continuation criteria (not initial)

Documentation Required

Clinical response / Prior therapy history — Documentation required

Document prior therapy history and clinical response. Provide evidence of a positive clinical response (for example, sustained abstinence, increased number of abstinent days, reduction in heavy drinking episodes, improved physical health or psychosocial functioning), or documentation that the patient previously improved on the therapy and the drug is being restarted due to relapse.

Document baseline and follow-up measures (abstinent days, heavy drinking episodes, functional improvements)
If restarting therapy after relapse, provide prior improvement documentation

Note

Continuation vs Initial Therapy

Distinguish initial versus continuation therapy on the prior authorization form. If this is a continuation (renewal) request, ensure you select the continuation pathway and supply required evidence of ongoing benefit per continuation criteria. Do NOT submit continuation requests under the initial-therapy pathway.

Select 'initial' for new starts and 'continuation' for renewals
Continuation requests must include documentation of ongoing benefit (see continuation criteria)

Pharmacotherapy and Programmatic Support Requirements

Pharmacotherapy with psychosocial support

Medication must be provided within a broader treatment program:

Medication plus psychosocial support: Acamprosate must be used as part of a comprehensive management program that includes psychosocial support.

Requests may be denied if the drug is not used within a comprehensive program including psychosocial interventions.

Background on Acamprosate Calcium

Acamprosate calcium (delayed‑release tablets) is indicated for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation. It is recommended that treatment with acamprosate be provided as part of a comprehensive management program that includes psychosocial support. The drug’s efficacy for promoting abstinence has not been demonstrated in patients who have not achieved abstinence prior to starting therapy, and its effectiveness in polysubstance abusers has not been adequately assessed.

Key Definitions

inv-09: Abstinence at treatment initiation — Definition and limitations

DefinitionPatient is abstinent from alcohol at the time acamprosate treatment begins (i.e., has undergone detoxification and achieved alcohol abstinence).

Efficacy limitationEfficacy has not been demonstrated in subjects who have not undergone detoxification and are not abstinent prior to treatment initiation.

Program requirementTreatment should be used as part of a comprehensive management program that includes psychosocial support.

Polysubstance noteEfficacy in promoting abstinence in polysubstance abusers has not been adequately assessed.